A Spiral Wire Technique for Producing Gradually Occlusive Coronary Thrombosis

Blair, Emil; Nygren, Edward J.; Cowley, R. Adams

doi:10.1016/s0022-5223(19)33545-7

Cited by 34 publications

(2 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Precipitation of intracoronary thrombus was attempted by electrical stimulation of the coronary intima,10) an infusion of thrombin into the coronary artery,11) or insertion of a copper coil into the coronary artery . 12) In preliminary trials to precipitate intracoronary thrombus within a few hours, a combination of electrical stimulation and thrombin infusion was found to be the most reliable method. The intracoronary thrombus or its conditions were confirmed in every experimental animal by autopsy at the end of the experiment.…”

Section: Discussionmentioning

confidence: 99%

Experimental study on the comparative thrombolytic effects of intracoronary and intravenous administration of urokinase.

Tomoda

1986

Jpn Heart J

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Experimental study on the comparative thrombolytic effects of intracoronary and intravenous administration of urokinase.

Tomoda

1986

Jpn Heart J

View full text Add to dashboard Cite

“…The coronary thrombosis model used in this study was first described by Blair et al (14) and later modified by other investigators (15,16). A fourth intercostal space thoracotomy was performed on the left side, and the heart was suspended in a pericardial cradle.…”

Section: Surgical Procedures and Instrumentationmentioning

confidence: 99%

Local proCPU (TAFI) Activation during Thrombolytic Treatment in a Dog Model of Coronary Artery Thrombosis can be Inhibited with a Direct, Small Molecule Thrombin Inhibitor (Melagatran)

Mattsson¹,

Björkman²,

Abrahamsson³

et al. 2002

Thromb Haemost

View full text Add to dashboard Cite

SummaryTo test the hypothesis that the direct thrombin inhibitor, melagatran is able to inhibit local pro-carboxypeptidase U (proCPU) activation that occurs during thrombolytic treatment, t-PA alone, or in combination with melagatran, was given to dogs with a coronary artery thrombosis. Blood samples from the great cardiac vein and aorta were collected at baseline, during thrombus formation, throughout the t-PA±melagatran infusion and during the patency period, for analysis of CPU activity using a novel assay. A higher CPU activity in venous compared to arterial blood (V-A difference) indicates CPU activation in coronary vessels.Efficacy was assessed by determination of time to lysis, duration of patency and blood flow during patency. Dogs (n = 26) were randomized to receive either 1) t-PA, 1 mg/kg as an intravenous 20-min infusion; 2) t-PA as in group 1,+ melagatran bolus, 0.3 mg/kg, followed by a 3-h infusion (0.15 mg/kg per h); 3) sham-operated but no coronary thrombus, and administered t-PA as for Group 1. All groups had similar baseline characteristics. Significant increases in CPU activity were observed in Groups 1 and 2 during thrombus formation, with V-A differences of 5.5 and 4.5 U/L, respectively. No significant V-A difference was observed in the sham-operated group. CPU activity increased in Group 1 during the t-PA infusion (V-A difference 15.9 U/L), whereas the V-A difference in Group 2 decreased to 2.6 U/L following melagatran treatment. These results demonstrate that melagatran attenuates generation of CPU in the coronary circulation. The mechanism is probably indirect, via inhibition of thrombin-mediated activation of proCPU.

show abstract